- Pneumococcal
- Adults who have had PCV13
Which adults ages 19–64 years should receive a second dose of PPSV23 before age 65?
A second PPSV23 given 5 years after the first dose is recommended for people age 19 through 64 years who were vaccinated with PCV13 and PPSV23 and who have one of the following:
- functional or anatomic asplenia (including persons with sickle cell disease or splenectomy patients)
- chronic renal failure (including dialysis patients) or nephrotic syndrome
- immunocompromise (including HIV infection)
- leukemia, lymphoma, Hodgkin disease, multiple myeloma, generalized malignancy
- immunosuppressive therapy (including long-term systemic corticosteroids or radiation therapy)
- solid organ transplant